Compare EMAT & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EMAT | ALMR |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 2021 | 2026 |
| Metric | EMAT | ALMR |
|---|---|---|
| Price | $0.93 | $30.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $8.25 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 787.6K | 728.8K |
| Earning Date | 08-17-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $64.80 |
| Revenue Next Year | $3,807.38 | $37.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $21.58 |
| 52 Week High | $17.50 | $39.61 |
| Indicator | EMAT | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 31.48 | 52.11 |
| Support Level | N/A | $23.87 |
| Resistance Level | $1.69 | $37.81 |
| Average True Range (ATR) | 0.27 | 2.56 |
| MACD | -0.03 | 0.20 |
| Stochastic Oscillator | 1.82 | 56.19 |
Evolution Metals & Technologies Corp is a critical materials and technology company. The company is focused on developing a secure, dependable, and self-sustaining U.S.-aligned supply chain for critical minerals and materials (CMM), and rare earth elements (REEs). The company is also engaged in recycling end-of-life materials through urban mining to help strengthen domestic resource independence and long-term supply stability.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.